Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Farm. hosp ; 35(supl.2): 25-31, 2011. tab
Artigo em Espanhol | IBECS | ID: ibc-145096

RESUMO

En la validación de la quimioterapia oral, el farmacéutico debe comprobar la idoneidad de la prescripción, así como la corrección de su contenido, aplicando los mismos estándares de seguridad para los citostáticos parenterales. Cada vez hay más cánceres que tienen disponibles tratamientos por vía oral, mejorando la satisfacción del paciente, ya que pueden tomarse en sus domicilios sin necesidad de visitar el hospital. A medida que se incrementen los tratamientos citostáticos por vía oral será mucho más importante asegurarse de que ese cumplimiento de los tratamientos sea lo más óptimo posible. Los nuevos citostáticos por vía oral son menos tóxicos, reducen los costes indirectos e implican una menor pérdida de tiempo para el paciente y sus cuidadores, pero sus costes deberían estar por debajo de un umbral aceptado por la sociedad. Para ayudar a esta toma de decisiones, deberemos emplear las herramientas que la farmacoeconomía pone en nuestras manos (AU)


When validating oral chemotherapy, pharmacists should confirm the suitability and correctness of the prescription, applying the same safety standards as those used for parenteral cytostatic drugs. There are an increasing number of cancers for which orally administered drugs are available, which increases patient satisfaction as these drugs can be taken at home without the need to visit a hospital. As oral cytostatic treatments increase, so does the importance of ensuring optimal treatment compliance. The new oral cytostatic agents are less toxic, reduce indirect costs and imply less loss of time for patients and their families. However, the cost of these agents should be below a threshold acceptable for society. As an aid to decision making, pharmacoeconomic tools should be used (AU)


Assuntos
Humanos , Custos de Medicamentos/tendências , Farmacoeconomia/organização & administração , Citostáticos/uso terapêutico , Antineoplásicos/uso terapêutico , Neoplasias/tratamento farmacológico , Tomada de Decisões , Segurança do Paciente
2.
Ecancermedicalscience ; 3: 145, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-22276010

RESUMO

In the fight against cancer, new and more specific targets are needed. Here, we offer an example of a potential target that has not been widely studied, namely the syncytin protein. Syncytin is expressed mainly in the human placenta and is implicated in placental syncytiotrophoblast cell fusion. Not much is known about the role of syncytin in cancer, but the existing data call for more intense research. Its retroviral origin and particular tissue distribution make syncytin an interesting potential target in cancer therapy.

3.
Clin. transl. oncol. (Print) ; 10(11): 688-696, nov. 2008. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-123543

RESUMO

Langerhans cell histiocytosis (LCH) is a poorly understood proliferative disease, with different patterns of clinical presentation. Currently it is classified according to the number and type of system involved and the degree of organ dysfunction. The aetiology of the disease remains uncertain, and in some cases the disease is polyclonal, suggesting a reactive condition. Many cytokines have been implicated in the pathogenesis of LCH. Different therapeutic approaches can be considered depending on the affected organ, including surgery, radiotherapy and chemotherapy. Long-term organ dysfunction may remain, despite disease control and/or eradication, making indefinite supportive treatment mandatory. Here we present a literature review on all of the aspects of the disease, treatment approaches and existing protocols, and finally an adult clinical case (AU)


No disponible


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Histiocitose de Células de Langerhans/imunologia , Histiocitose de Células de Langerhans/patologia , Histiocitose de Células de Langerhans/terapia , Estudos Multicêntricos como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Terapia Combinada , Citocinas/fisiologia , Citostáticos/uso terapêutico , Células de Langerhans/patologia , Especificidade de Órgãos , Prognóstico , Recidiva
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...